ARTICLE | Company News

Roche drops Phase II Fragile X program

September 12, 2014 2:40 AM UTC

Roche (SIX:ROG; OTCQX:RHHBY) said it will discontinue development of RG7090 to treat Fragile X syndrome, for which the negative modulator of metabotropic glutamate receptor subtype 5 (mGluR5; GRM5) was in Phase II testing. In a letter to Fragile X patients, the pharma said it made the decision based on negative Phase II results. In the 183-patient Phase II Fragxis trial, RG7090 missed the primary endpoint of improving Anxiety Depression and Mood Scale (ADAMS) total scores at week 12 vs. placebo. ...